89 related articles for article (PubMed ID: 22187803)
1. Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir.
Tripathi S; Chandalia HB; Rao PV; Badgandi M; Patni R; Subbanna PK; Shetty R; Kumar H
J Indian Med Assoc; 2011 Apr; 109(4):275-8. PubMed ID: 22187803
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L
Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
[TBL] [Abstract][Full Text] [Related]
3. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
Dornhorst A; Lüddeke HJ; Sreenan S; Kozlovski P; Hansen JB; Looij BJ; Meneghini L;
Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
[TBL] [Abstract][Full Text] [Related]
4. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
Meneghini L; Koenen C; Weng W; Selam JL
Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
[TBL] [Abstract][Full Text] [Related]
5. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
6. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
[TBL] [Abstract][Full Text] [Related]
7. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
8. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
Marre M; Pinget M; Gin H; Thivolet C; Hanaire H; Robert JJ; Fontaine P
Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118
[TBL] [Abstract][Full Text] [Related]
9. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
10. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
Raslová K; Bogoev M; Raz I; Leth G; Gall MA; Hâncu N
Diabetes Res Clin Pract; 2004 Nov; 66(2):193-201. PubMed ID: 15533587
[TBL] [Abstract][Full Text] [Related]
11. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
[TBL] [Abstract][Full Text] [Related]
12. [The safety and effectiveness of once daily detemir in patients with type 2 diabetes previously failing oral agents: the Chinese cohort from SOLVE(TM) observational study].
Pan CY; Ji LN; Lu JM; Yang WY; Zhou ZG; Zou DJ; Ji QH; Han P; Liu J; Li Q; Su BL; Li YB; Gao ZN; Wang PH; Yin SN; Dong YH; Yang T; Sun K; Li H; Hong X; Lin J; Shi JM; Yang XJ; Fang H; Yan XD;
Zhonghua Nei Ke Za Zhi; 2013 Jan; 52(1):11-5. PubMed ID: 23710808
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
[TBL] [Abstract][Full Text] [Related]
14. Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: subgroup analysis of the SOLVE study.
Pan C; Han P; Ji L; Ji Q; Lu J; Lin J; Liu J; Su B; Shi J; Wang P
J Diabetes; 2015 Mar; 7(2):222-30. PubMed ID: 24909984
[TBL] [Abstract][Full Text] [Related]
15. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study.
Yenigun M; Honka M
Int J Clin Pract; 2009 Mar; 63(3):425-32. PubMed ID: 19222627
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
17. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
Hermansen K; Davies M
Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
[TBL] [Abstract][Full Text] [Related]
18. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
Valensi P; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y;
Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
[TBL] [Abstract][Full Text] [Related]
19. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.
Ross S; Dzida G; Ji Q; Kaiser M; Ligthelm R; Meneghini L; Nazeri A; Orozco-Beltran D; Pan C; Svendsen AL;
J Diabetes; 2014 May; 6(3):243-50. PubMed ID: 24103141
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study.
Soewondo P; Kshanti IA; Pramono RB; Langi YA; Dalem-Pemayun TG
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S47-53. PubMed ID: 23647719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
